New treatment option shows promise for severe hypertrophic cardiomyopathy in children

New treatment option shows promise for severe hypertrophic cardiomyopathy in children

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK pathway, according to a study published in JACC: Basic to Translational Science.

​Medical Xpress – latest medical and health news stories

Read More


Discover more from Nurse Unity Chats

Subscribe to get the latest posts sent to your email.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *